About US
HDT Bio is a Seattle-based clinical stage biopharmaceutical development company developing advanced RNA vaccine products to harness immune system’s response against a variety of disease conditions. HDT Bio’s innovative vaccine platform aims to stabilize and deliver RNA to the immune system to prevent or treat infectious diseases and cancer. Its AMPLIFY vaccine platform is the first self-replicating RNA (repRNA) to receive regulatory authorization anywhere in the world.
Multidisciplinary Team
HDT Bio’s multidisciplinary team brings extensive regulatory, business, scientific and clinical development experience needed to navigate the intricate process of bringing new products to market, from ideation to regulatory approval, enabling us to deliver unique solutions that transform healthcare.
Driving Clinical Development Excellence
HDT Bio’s commitment to excellence in clinical development is evident in its track record of establishing connections with leading academic medical centers, government organizations and foundations both domestically and internationally towards achieving clinical development success. By capitalizing on its previous experience, HDT Bio streamlines the development process, expedites clinical trials, and brings life-saving vaccines to patients in need.
Embracing Diversity and Inclusion
By fostering a diverse workforce, HDT Bio taps into a range of perspectives, experiences, and talents, promoting innovation and ensuring that its solutions meet the unique needs of diverse patient populations.
Global Value Creation
By providing safe, effective, and innovative products that improve lives around the world, HDT Bio is poised for significant growth through global clinical trials, government grants, and strategic partnerships. Making HDT Bio’s products widely available allows the company to make a meaningful difference on a global scale and realize success in multiple markets.
Achieving Global Health Equity
HDT Bio is dedicated to combining for-profit goals with global health equity objectives. The company’s strategy emphasizes an integrative approach, generating platform and product validation through international partnerships that accelerate pathways to patient access globally. By leveraging both RNA platforms in infectious diseases and exploration of new therapeutic areas, HDT Bio delivers life-changing solutions that have a positive impact on patients, healthcare providers, and society.
